The federal government is moving toward a nationwide ban on certain products containing elevated levels of 7-hydroxymitragynine, commonly called 7-OH. However, the action is not intended to ban traditional kratom leaf that contains only naturally occurring trace amounts of 7-OH.
On July 1, 2026, the Drug Enforcement Administration announced its intent to temporarily place 7-OH above a specified threshold into Schedule I of the Controlled Substances Act. The official notice was published in the Federal Register on July 6.
Although some headlines are calling this an immediate ban, the scheduling order has not taken effect yet. The DEA cannot issue the temporary order before August 5, 2026, and the exact effective date will depend on when a final temporary scheduling order is published.
What Is 7-OH?
7-OH is an alkaloid related to the kratom plant, Mitragyna speciosa. It occurs naturally in kratom leaf in very small amounts (around .001-.007%), but it can also be produced or concentrated through chemical and manufacturing processes.
In recent years, highly concentrated 7-OH products have become increasingly common online and in convenience stores. These products can contain 100x to over 1000x more 7-OH than traditional kratom leaf.
Federal agencies say they are particularly concerned about products containing synthesized, isolated or artificially elevated levels of 7-OH. The DEA describes 7-OH as having opioid-like activity and cites concerns involving dependence, tolerance, respiratory depression, unclear dosing and inconsistent product labeling.
What Is the DEA Proposing?
The DEA’s proposal would temporarily classify 7-OH products exceeding a specified threshold as Schedule I controlled substances.
The proposed threshold generally includes:
- Botanical kratom material containing more than 0.050% 7-OH by dry weight.
- Certain synthetic or processed products containing more than 0.050% 7-OH.
- Certain products containing more than 1 milligram of 7-OH, depending on the product’s form and method of production.
The proposal could therefore apply to concentrated tablets, gummies, shots, extracts, pressed pills and other processed products when their 7-OH content exceeds the threshold.
The government is also pursuing Schedule I placement for three related substances:
- Mitragynine pseudoindoxyl, also called MP
- MGM-15
- MGM-16
Unlike naturally occurring trace levels of 7-OH, federal officials state that these three related substances do not naturally occur in the kratom plant.
Is Traditional Kratom Leaf Being Banned?
According to the DEA, FDA and Department of Health and Human Services, this federal action is not intended to ban traditional botanical kratom containing naturally occurring levels of 7-OH below the proposed threshold.
That distinction is extremely important.
Traditional kratom powder is made by drying and grinding the leaves of the kratom tree. It naturally contains a range of alkaloids, with mitragynine generally being the primary alkaloid and 7-OH occurring in much smaller amounts.
Enhanced 7-OH products are different. They are often specifically manufactured to isolate, increase or deliver large amounts of a single alkaloid. While some sellers market these products as ordinary kratom, their composition and strength can be very different from traditional leaf products.
The current federal action is aimed at products above the government’s proposed concentration limits—not all kratom products.
When Would the Federal Ban Begin?
The Federal Register notice was published on July 6, 2026. The DEA must wait at least 30 days before issuing the temporary scheduling order, meaning the order cannot be issued before August 5, 2026.
This does not necessarily mean the ban will automatically begin on August 5. That is simply the earliest date the DEA may issue the order.
The order would become effective on the date it is published in the Federal Register. Once effective, the temporary Schedule I placement would last for two years, with the possibility of a one-year extension while the government considers permanent scheduling.
What Would Schedule I Placement Mean?
Once the temporary order takes effect, manufacturing, distributing, selling or possessing products covered by the order would be subject to the federal Controlled Substances Act.
Businesses carrying products above the threshold would need to remove them from sale. Consumers should also understand that possession of covered products could carry federal legal consequences after the order becomes effective.
Because the final order has not yet been issued, consumers and retailers should watch for additional announcements instead of assuming that every kratom-related product will become illegal on a specific date.
Why the Difference Between Kratom and Enhanced 7-OH Matters
Treating traditional kratom leaf and enhanced 7-OH products as if they are identical creates confusion for consumers, regulators and responsible businesses.
Traditional kratom has a long history of botanical use in Southeast Asia. Enhanced 7-OH products represent a newer category of concentrated products that may deliver alkaloid levels far beyond those naturally found in ordinary leaf.
Clear labeling, appropriate testing and reasonable concentration limits can help consumers understand what they are purchasing. Regulations should also clearly distinguish traditional botanical products from products that have been synthetically altered or substantially enhanced.
Our Position at High Sierra Herbals
At High Sierra Herbals, we support responsible standards that protect consumers and hold manufacturers accountable for accurate labeling and product quality.
We also believe it is essential for regulators and the public to understand that traditional kratom leaf is not the same as a highly concentrated or synthetically enhanced 7-OH product.
We have chosen to never carry any 7-OH products. It was a decision based around the strength and mislabeling of these products which we believe could put consumers at risk and also put natural leaf kratom at legal risk as well.
We do believe 7-OH can be beneficial for people managing chronic pain and should be available to those who need it. However there are certain brands in the 7-OH market mislabeling products as all natural and as kratom while one pill contains the amount of 7-OH found in a entire kilo of kratom powder. Some 7-OH brands have also marketed their products to mimic pharmaceuticals. This type of advertising brings negative attention and scrutiny to the whole kratom industry. We built High Sierra Herbals with the mindset of plants over pills. We do not support any companies that do not align with our same beliefs.
Consumers deserve transparent information, properly tested products and regulations based on meaningful distinctions between botanical kratom and isolated alkaloid products. Broad or confusing policies could unfairly affect responsible businesses and adult consumers without addressing the products that created the greatest concern.
Staying Informed
The federal 7-OH situation is developing quickly. The temporary scheduling order could be issued as early as August 5, but its exact effective date and final wording will not be known until the DEA publishes the order.
We will continue monitoring the situation and sharing updates as reliable information becomes available.
This article is provided for general informational purposes and should not be considered legal or medical advice. Federal and state laws may change, and requirements may vary depending on location.
